Zacks Rating on PAREXEL International Corporation (PRXL)

PAREXEL International Corporation (PRXL) has an average broker rating of 2.33, which is interpreted as a Buy, as rated by 12 equity analysts. Nonetheless, 5 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 6 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.

PAREXEL International Corporation (PRXL) : The highest level PAREXEL International Corporation (PRXL) is projected to reach is $80 for the short term and the lowest estimate is at $49. The consolidated price target from 7 rating analysts who initiate coverage on the stock is $70.21 and the possibility the share price can swing is $10.11.


PAREXEL International Corporation has dropped 0.17% in the last five trading days, however, the shares have posted positive gains of 7.82% in the last 4 weeks. PAREXEL International Corporation is up 13.65% in the last 3-month period. Year-to-Date the stock performance stands at 2.2%. PAREXEL International Corporation (NASDAQ:PRXL): The stock was completely flat for the day, closing at $69.62 on Tuesday. The flat closing masks the intraday volatility in the stock. After opening at $69.58, the stock touched an intraday high of $70.39 and a low of $69.43. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $69.62. The total trading volume on Tuesday was 247,130.

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world. The Company operates through three segments: Clinical Research Services, PAREXEL Consulting Services and PAREXEL Informatics. Its product and service offerings include clinical trials management, data management, epidemiology, health economics/outcomes research, pharmacovigilance, medical communications, clinical pharmacology, patient recruitment, clinical supply and drug logistics, post-marketing surveillance, medical imaging services, electronic data capture systems, clinical trial management systems, Web-based portals, and other product development tools and services.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.